By HathawayMD.com Clinical Research Team | January 31, 2026
When considering MEDVi's telehealth weight loss program, patients face a fundamental choice: compounded semaglutide or compounded tirzepatide. Both medications produce significant weight loss results, but they work through different mechanisms and come with distinct cost profiles. This evidence-based comparison will help you make an informed decision.
For complete background on MEDVi's platform structure and enrollment process, our detailed MEDVi analysis covers the essential foundations.
The Science Behind Each Medication
Semaglutide Mechanism: Semaglutide is a GLP-1 receptor agonist that mimics a naturally occurring hormone. It works primarily by activating appetite-regulating pathways in the brain, slowing gastric emptying, and enhancing glucose-dependent insulin secretion. This single-receptor approach has proven highly effective, with FDA-approved semaglutide (Wegovy) producing average weight loss of approximately 14.9% over 68 weeks in clinical trials.
Tirzepatide Mechanism: Tirzepatide takes a dual-action approach, activating both GLP-1 and GIP receptors simultaneously. This combined mechanism appears to enhance metabolic effects beyond what either receptor agonist achieves alone. The GIP component adds appetite suppression and may improve insulin sensitivity through additional pathways.
Clinical Trial Evidence: Head-to-Head Results
The most definitive comparison comes from the SURMOUNT-5 trial, a phase 3b study published in the New England Journal of Medicine in May 2025. This open-label trial directly compared tirzepatide to semaglutide in 751 adults with obesity but without type 2 diabetes over 72 weeks.
Weight Loss Results: Tirzepatide participants lost an average of 20.2% of body weight, compared to 13.7% for semaglutide. The difference of 6.5 percentage points was statistically significant (P<0.001). In practical terms, a 200-pound person could expect to lose approximately 40 pounds on tirzepatide versus 27 pounds on semaglutide.
Waist Circumference: Tirzepatide reduced waist circumference by 18.4 cm compared to 13.0 cm for semaglutide. This metric matters because abdominal fat correlates strongly with cardiovascular and metabolic risk.
Real-world data supports these findings. Meta-analyses of clinical trials and retrospective studies show tirzepatide consistently produces greater weight loss, with effects appearing dose and duration-dependent.
MEDVi Pricing Comparison
The enhanced efficacy of tirzepatide comes with a price premium through MEDVi:
Compounded Semaglutide: First month at $179, refills at $299 monthly. Annual cost approximately $3,468 (first year).
Compounded Tirzepatide: First month at $279-$349, refills at $399-$499 monthly. Annual cost approximately $4,668-$5,838 (first year).
The tirzepatide premium works out to roughly $100-$200 monthly, or $1,200-$2,400 annually. Whether that premium justifies the enhanced results depends on individual circumstances and weight loss goals.
Side Effect Profiles
Both medications share similar side effects, primarily affecting the gastrointestinal system:
Common to Both: Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. These symptoms typically occur during dose titration and improve over time for most patients.
Comparative Data: Research suggests tirzepatide may cause slightly more nausea and vomiting compared to semaglutide, though the severity varies considerably between individuals. The SURMOUNT-5 trial found no significant overall difference in gastrointestinal adverse events between the two medications.
Serious Risks (Both Medications): Thyroid tumor risk (observed in animal studies), acute pancreatitis, gallbladder disease, kidney function impairment, and hypoglycemia when combined with certain diabetes medications. Contraindications include personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.
Who Should Choose Semaglutide Through MEDVi?
Semaglutide may be the better starting point for:
First-Time GLP-1 Users: If you've never tried GLP-1 therapy, starting with semaglutide makes practical sense. It's less expensive, and you can always switch to tirzepatide if results plateau. Many patients achieve excellent results with semaglutide alone.
Budget-Conscious Patients: The $1,200-$2,400 annual savings adds up, especially for long-term maintenance therapy. Some patients prefer allocating those funds toward nutrition coaching or fitness programs.
Patients with GI Sensitivity: If you have a history of significant nausea or digestive issues, semaglutide's single-receptor mechanism might produce more tolerable side effects during the adjustment period.
Moderate Weight Loss Goals: For patients needing to lose 10-15% of body weight, semaglutide's clinical profile may be entirely sufficient without the added cost of tirzepatide.
Who Should Consider Tirzepatide Through MEDVi?
Tirzepatide may be worth the premium for:
Semaglutide Non-Responders: If you've tried semaglutide (through MEDVi or elsewhere) with inadequate results, tirzepatide's dual mechanism offers a clinically validated alternative. The different receptor profile may produce better results for your specific metabolism.
Aggressive Weight Loss Goals: Patients needing to lose 20% or more of body weight may benefit from tirzepatide's enhanced efficacy. The additional 6-7% weight loss compared to semaglutide could be meaningful for health outcomes.
Patients with Type 2 Diabetes: While both medications improve glycemic control, tirzepatide's dual mechanism may offer additional benefits for blood sugar regulation. Discuss this with your MEDVi provider if you have diabetes.
Long-Term Investment Mindset: If your budget allows and you're committed to maximizing results, tirzepatide offers the most powerful currently available GLP-1 option. The enhanced efficacy may reduce total treatment duration needed to reach goal weight.
Switching Between Medications
One advantage of MEDVi's platform is flexibility. You're not locked into a single medication choice:
Semaglutide to Tirzepatide: Patients who start with semaglutide and plateau can request switching to tirzepatide. Your provider will adjust dosing protocols appropriately. Expect an adjustment period as your body adapts to the dual-receptor mechanism.
Tirzepatide to Semaglutide: Less common, but some patients switch to semaglutide for cost reasons after achieving their goal weight. Maintenance dosing may be effective at the lower price point for weight maintenance.
Administration Differences
Both medications are available through MEDVi as weekly injections or daily dissolvable tablets:
Injections: Once-weekly subcutaneous injections are the most common format. MEDVi provides instructions for proper injection technique. Many patients find weekly injections more convenient than daily pills.
Tablets: Daily dissolvable tablets offer a needle-free option for injection-averse patients. Clinical data suggests tablets may be somewhat less effective than injections for weight loss, though many patients achieve good results with this format.
Making Your Decision
The choice between MEDVi semaglutide and tirzepatide ultimately depends on balancing efficacy goals, budget constraints, and individual medical factors. Neither choice is wrong—both medications produce clinically significant weight loss when combined with appropriate lifestyle modifications.
For most first-time patients, we suggest starting with semaglutide. The lower cost allows you to assess your response to GLP-1 therapy with less financial commitment. If results are satisfactory, you've saved money. If results plateau, switching to tirzepatide remains an option.
For patients who've already tried semaglutide without adequate results, or those with aggressive weight loss timelines and appropriate budgets, tirzepatide offers demonstrably superior efficacy backed by robust clinical evidence.
This comparison is informational only and doesn't replace consultation with a licensed healthcare provider. Individual responses to medications vary, and prescription eligibility is determined by qualified clinicians based on thorough medical evaluation.
Frequently Asked Questions About MEDVi Medication Options
Can I try both medications to see which works better? While it's possible to switch medications through MEDVi, you shouldn't take both at the same time. Patients typically commit to one medication for 3-6 months before considering a switch. This gives enough time to reach therapeutic doses and assess response properly.
How quickly can I switch if semaglutide doesn't work? If you're not seeing results after reaching maintenance dosing (usually 2-3 months), you can discuss switching with your MEDVi provider. There's no mandatory waiting period, but providers want to ensure you've given the first medication adequate time at full doses.
Are there any medications I shouldn't combine with these GLP-1s? Both semaglutide and tirzepatide can interact with other diabetes medications, particularly insulin and sulfonylureas, increasing hypoglycemia risk. They may also affect absorption of oral medications due to slowed gastric emptying. Disclose all medications to your MEDVi provider during intake.
Which medication has less severe side effects? Side effect profiles are similar, though some data suggests tirzepatide may cause slightly more nausea initially. Individual responses vary dramatically—some patients tolerate tirzepatide better than semaglutide and vice versa. There's no way to predict your specific response in advance.
If tirzepatide works better, why would anyone choose semaglutide? Cost is the primary factor. The $1,200-$2,400 annual savings with semaglutide matters for long-term treatment. Also, semaglutide has a longer track record with more years of real-world data. Some patients achieve their goals with semaglutide and don't need the enhanced efficacy of tirzepatide.